Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years



      Acne vulgaris is a ubiquitous condition in men and women starting in adolescence. It is often persistent and refractory to multiple treatment methods. Although multiple medications may be used on- or off-label for treatment, many adverse effects and risks exist with these treatments, and there has not been an agent with a novel mechanism of action introduced in 40 years. Clascoterone is a recently approved topical acne medication with the first novel mechanism of action since isotretinoin. The purpose of this article was to review the clinical data regarding the safety and efficacy of topical clascoterone for the treatment of acne vulgaris in male and female subjects aged >12 years.


      A literature search of PubMed, EMBASE, and MEDLINE was conducted for clinical trials published between January 2014 and March 2021 in the English language using the key words Winlevi, clascoterone, and acne vulgaris. Articles were selected if they were related to the approval by the US Food and Drug Administration of clascoterone or provided novel data regarding this drug entity.


      Two Phase III randomized controlled trials (NCT02608450 and NCT02608476) were ultimately selected, as these trials provided pivotal information to the US Food and Drug Administration for the approval of topical clascoterone.


      The findings of this review show that topical clascoterone is likely an effective and safe option for the treatment of acne vulgaris. It offers efficacy rates similar to those of current medications through a novel mechanism of action. Its place in therapy remains unclear, but it might be placed ahead of other androgen receptor antagonists such as spironolactone due to its avoidance of systemic side effects.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zaenglein AL.
        Acne vulgaris.
        N Engl J Med. 2018 Oct 4; 379 (PMID: 30281982): 1343-1352
        • Ng Q
        • Koh S
        • Shin D
        • et al.
        Use of polymethylmethacrylate (PMMA) microspheres collagen to treat atrophic acne scars.
        Med Hypotheses. 2017 Oct; 108 (Epub 2017 Aug 16. PMID: 29055383): 115-116
        • Zaenglein AL
        • Pathy AL
        • Schlosser BJ
        • et al.
        Guidelines of care for the management of acne vulgaris.
        J Am Acad Dermatol. 2016 May; 74 (e33Epub 2016 Feb 17. Erratum in: J Am Acad Dermatol. 2020 Jun;82(6):1576. PMID: 26897386): 945-973
        • Ramrakha S
        • Fergusson DM
        • Horwood LJ
        • et al.
        Cumulative mental health consequences of acne: 23-year follow-up in a general population birth cohort study.
        Br J Dermatol. 2016;
        • O'Neill AM
        • Gallo RL.
        Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris.
        Microbiome. 2018 Oct 2; 6 (PMID: 30285861; PMCID: PMC6169095): 177
      1. [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006. Acne: Overview. 2013 Jan 16 [Updated 2019 Sep 26]. Available from:

      2. Elliot W. Clascoterone cream 1% (Winlevi®) [Internet]. 2020 [cited 2021Feb25]. Available from:

        • Sato K
        • Matsumoto D
        • Iizuka F
        • et al.
        Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians.
        Aesthetic Plast Surg. 2006 Nov-Dec; 30 (PMID: 17077951): 689-694
      3. Winlevi® (clascoterone) [package Insert]. Lainate, Italy: Cassiopea, Inc; 2020.

        • Hebert A
        • Thiboutot D
        • Stein Gold L
        • et al.
        Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials.
        JAMA Dermatol. 2020 Jun 1; 156 (PMID: 32320027; PMCID: PMC7177662): 621-630
      4. Prescription price comparison: compare drug prices [Internet]. 2021 [cited 2021Mar5]. Available from:

      5. Blink Health Online Pharmacy & Discount Prescriptions. Blink Health; 2021 [cited 2021Mar5]. Available from:

      6. Winlevi prices and discount coupons [Internet]. America's Pharmacy. America's Pharmacy; 2021 [cited 2021Mar5]. Available from: